BioSpace News Archive

In four clinical trials being presented today during the 59th ASH Annual Meeting and Exposition in Atlanta, researchers report promising results suggesting patients with blood disorders and several types of cancer will soon have significantly expanded options for treatment.

DNAnexus announced the availability of the DeepVariant bioinformatics tool on the DNAnexus Platform.

The timing and actual number of Shares purchased will depend on a variety of factors including regulatory restrictions on price, manner, timing, and volume, corporate and other regulatory requirements.

NextCollect is being offered to both existing contracted clients and to new customers through an online ordering web distribution portal.

The PhRMA today announced a new multi-year, multimillion dollar initiative to address the opioid crisis, which will include a partnership with the Addiction Policy Forum to fund state and local programs, as well as support for new public policies that help families and individuals impacted by the crisis.

Sutro plans to submit an investigational new drug application by the end of 2017 and to launch a Phase 1 clinical trial in the first quarter of 2018 to evaluate the safety and preliminary efficacy of STRO-001 in patients with multiple myeloma and aggressive and indolent, or slow-growing, lymphomas.

Under the terms of the license agreement, ZAO will be responsible for obtaining regulatory approvals for Aggrastat from Russia’s Ministry of Health, then executing the commercial launch and subsequent sale and marketing of Aggrastat in the territory.

Linear Health Sciences today announced additional investment funding of $1.538 million, bringing total company financing to nearly $3M.

This patent is supported by an additional 5 patents issued earlier by the U.S. Patent and Trademark Office (US 9,266,884, US 9,518,053, US 9,593,114, US 9,717,729, and US 9,802,933) which provide intellectual property protection for SF0166 and its analogs for composition of matter and methods of use through 2034.

For CTX001, CRISPR and Vertex will equally share all research and development costs and profits worldwide.